QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.064535v1 309/3/861    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beyer, T. P. Articles by Cao, G. Search for Related Content PubMed PubMed Citation Articles by Beyer, T. P. Articles by Cao, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

CARDIOVASCULAR

Coadministration of a Liver X Receptor Agonist and a Peroxisome Proliferator Activator Receptor- Agonist in Mice: Effects of Nuclear Receptor Interplay on High-Density Lipoprotein and Triglyceride Metabolism in Vivo

Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, Indiana (T.P.B., R.J.S., P.F., Y.Z., J.D., W.R.B., R.F.K., H.G., T.P.R., S.K.K., P.I.E., G.C.); and State University of New York, Downstate Medical Center, Brooklyn, New York (X.-C.J.)

Liver X receptors (LXRs) are master transcription factors regulating cholesterol and fatty acid metabolism. Treatment of C57B6 mice with a specific synthetic LXR agonist, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1(trifluoromethyl)-ethyl]phenyl]-benzenesulfonamide (T0901317), resulted in elevated high-density lipoprotein (HDL) cholesterol as well as plasma and liver triglycerides. Peroxisome proliferator-activated receptor- (PPAR) agonists are known to induce peroxisomal fatty acid -oxidation and also mediate HDL cholesterol metabolism. We have explored the hypothesis that simultaneous activation of PPAR and LXR may lead to additive effects on HDL cholesterol elevation as well as attenuation of triglyceride accumulation. Coadministration of T0901317 and the specific PPAR agonist [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy14643)] in mice led to synergistic elevation of HDL cholesterol that was primarily associated with enlarged HDL particles enriched with apoE and apoAI. Liver phospholipid transfer protein (PLTP) mRNA and plasma PLTP activity were additively elevated, suggesting a role of PLTP in the observed HDL cholesterol elevation. Moderate increases in plasma triglyceride levels induced by LXR activation was reduced, whereas the accumulation of triglyceride in the liver was not altered upon coadministration of the PPAR agonist. Peroxisomal fatty acid -oxidation in the liver was dramatically elevated upon PPAR activation as expected. Interestingly, activation of LXRs via T0901317 also led to a significant increase in peroxisomal fatty acid -oxidation. Sterol regulatory element binding protein 1c expression was dramatically up-regulated by the LXR agonist but was not changed with PPAR agonist treatment. Liver lipoprotein lipase expression was additively increased upon LXR agonist and PPAR agonist coadministration. Our studies mark the first exploration of nuclear receptor interplay on lipid homeostasis in vivo.

Address correspondence to: Dr. Guoqing Cao, Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285. E-mail: guoqing_cao{at}lilly.com

This article has been cited by other articles:

				M. Penza, C. Montani, A. Romani, P. Vignolini, B. Pampaloni, A. Tanini, M. L. Brandi, P. Alonso-Magdalena, A. Nadal, L. Ottobrini, et al. Genistein Affects Adipose Tissue Deposition in a Dose-Dependent and Gender-Specific Manner Endocrinology, December 1, 2006; 147(12): 5740 - 5751. [Abstract] [Full Text] [PDF]

				D. Patsouris, J. K. Reddy, M. Muller, and S. Kersten Peroxisome Proliferator-Activated Receptor {alpha} Mediates the Effects of High-Fat Diet on Hepatic Gene Expression Endocrinology, March 1, 2006; 147(3): 1508 - 1516. [Abstract] [Full Text] [PDF]

				D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]

				L. K. Curtiss, D. T. Valenta, N. J. Hime, and K.-A. Rye What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport? Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 12 - 19. [Abstract] [Full Text] [PDF]

				T. Kino and G. P. Chrousos Combating Atherosclerosis With LXR{alpha} And PPAR{alpha} Agonists: Is Rational Multitargeted Polypharmacy the Future of Therapeutics in Complex Diseases? Mol. Interv., October 1, 2004; 4(5): 254 - 257. [Abstract] [Full Text] [PDF]